Data suggest that taletrectinib “provides clinically meaningful tumor shrinkage and prolonged disease control as a treatment option for advanced ROS1+ NSCLC, regardless of treatment history,” ...

The FDA is evaluating a new drug application for taletrectinib in patients with ROS1 fusion–positive non–small cell lung ...

Augtyro (repotrectinib), a tyrosine kinase inhibitor (TKI) targeting ROS1 and NTRK, has been cleared for patients with ROS1-positive non-small-cell lung cancer (NSCLC) on the back of overall ...

Nuvation Bio (NYSE:NUVB) said the FDA has accepted its application with priority review for its therapy taletrectinib in the treatment of advanced ROS1+ non-small cell lung cancer.

Despite solid data, the lack of high-value indications and no unique platform makes Nuvalent's valuation seem inflated; I ...